Manila Times Business
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
Approval is based on results from the OASIS 4 trial, which investigated semaglutide tablets 25 mg in adults living with obesity and overweight versus placebo in addition to diet and exerciseSemaglutide tablets will be available as a once-daily treatment, an alternative to weekly injections for adults living with obesity or overweight with a weight-related condition, alongside diet and exerciseAfter this approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), Novo Nordi
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Committed to care: How medical services sustain navy readiness
2h ago
GIGABYTE Announces AERO X16 Now Available, Bringing Next-Gen AI Performance to an Ultra-Thin Copilot+ PC
3h ago
The Shilla Seoul Hosts South Korea's First LHW Asia-Pacific Membership Meeting
3h ago
Voltalia SA: Total number of shares and voting rights in the share capital as of May 31, 2026
3h ago